{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T07:52:21Z","timestamp":1789199541052,"version":"build-2803163510"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2015,8,8]],"date-time":"2015-08-08T00:00:00Z","timestamp":1438992000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2015,11]]},"DOI":"10.1007\/s00277-015-2468-y","type":"journal-article","created":{"date-parts":[[2015,8,6]],"date-time":"2015-08-06T21:06:41Z","timestamp":1438895201000},"page":"1845-1851","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Salvage chemotherapy of gemcitabine, dexamethasone, and cisplatin (GDP) for patients with relapsed or refractory peripheral T-cell lymphomas: a consortium for improving survival of lymphoma (CISL) trial"],"prefix":"10.1007","volume":"94","author":[{"given":"Byeong-Bae","family":"Park","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Won Seog","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheolwon","family":"Suh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-Yeop","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeong-A","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hoon-Gu","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Won Sik","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,8,8]]},"reference":[{"issue":"1","key":"2468_CR1","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S0959-8049(01)00344-6","volume":"38","author":"K Kim","year":"2002","unstructured":"Kim K, Kim WS, Jung CW, Im YH, Kang WK, Lee MH, Park CH, Ko YH, Ree HJ, Park K (2002) Clinical features of peripheral T-cell lymphomas in 78 patients diagnosed according to the Revised European-American lymphoma (REAL) classification. Eur J Cancer 38(1):75\u201381","journal-title":"Eur J Cancer"},{"issue":"8","key":"2468_CR2","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1023\/A:1008418727472","volume":"9","author":"A Lopez-Guillermo","year":"1998","unstructured":"Lopez-Guillermo A, Cid J, Salar A, Lopez A, Montalban C, Castrillo JM, Gonzalez M, Ribera JM, Brunet S, Garcia-Conde J, Fernandez de Sevilla A, Bosch F, Montserrat E (1998) Peripheral T-cell lymphomas: initial features, natural history, and prognostic factors in a series of 174 patients diagnosed according to the R.E.A.L. Classification. Ann Oncol 9(8):849\u2013855","journal-title":"Ann Oncol"},{"issue":"1","key":"2468_CR3","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1053\/j.seminhematol.2013.11.006","volume":"51","author":"NM Reddy","year":"2014","unstructured":"Reddy NM, Evens AM (2014) Chemotherapeutic advancements in peripheral T-cell lymphoma. Semin Hematol 51(1):17\u201324. doi: 10.1053\/j.seminhematol.2013.11.006","journal-title":"Semin Hematol"},{"issue":"10","key":"2468_CR4","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1002\/ajh.21824","volume":"85","author":"SO Yoon","year":"2010","unstructured":"Yoon SO, Suh C, Lee DH, Chi HS, Park CJ, Jang SS, Shin HR, Park BH, Huh J (2010) Distribution of lymphoid neoplasms in the Republic of Korea: analysis of 5318 cases according to the World Health Organization classification. Am J Hematol 85(10):760\u2013764. doi: 10.1002\/ajh.21824","journal-title":"Am J Hematol"},{"issue":"1","key":"2468_CR5","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1046\/j.1365-2141.2001.02743.x","volume":"113","author":"S Sallah","year":"2001","unstructured":"Sallah S, Wan JY, Nguyen NP (2001) Treatment of refractory T-cell malignancies using gemcitabine. Br J Haematol 113(1):185\u2013187","journal-title":"Br J Haematol"},{"issue":"12","key":"2468_CR6","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1023\/A:1008409601731","volume":"9","author":"PL Zinzani","year":"1998","unstructured":"Zinzani PL, Magagnoli M, Bendandi M, Orcioni GF, Gherlinzoni F, Albertini P, Pileri SA, Tura S (1998) Therapy with gemcitabine in pretreated peripheral T-cell lymphoma patients. Ann Oncol 9(12):1351\u20131353","journal-title":"Ann Oncol"},{"issue":"6","key":"2468_CR7","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.3109\/10428194.2012.739286","volume":"54","author":"YY Yao","year":"2013","unstructured":"Yao YY, Tang Y, Zhu Q, Zhuang Y, Cheng YM, Wang L, Zou LF (2013) Gemcitabine, oxaliplatin and dexamethasone as salvage treatment for elderly patients with refractory and relapsed peripheral T-cell lymphoma. Leuk Lymphoma 54(6):1194\u20131200. doi: 10.3109\/10428194.2012.739286","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"2468_CR8","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1002\/cncr.27733","volume":"119","author":"D Mahadevan","year":"2013","unstructured":"Mahadevan D, Unger JM, Spier CM, Persky DO, Young F, LeBlanc M, Fisher RI, Miller TP (2013) Phase 2 trial of combined cisplatin, etoposide, gemcitabine, and methylprednisolone (PEGS) in peripheral T-cell non-Hodgkin lymphoma: Southwest Oncology Group Study S0350. Cancer 119(2):371\u2013379. doi: 10.1002\/cncr.27733","journal-title":"Cancer"},{"issue":"11","key":"2468_CR9","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1007\/s00277-012-1518-y","volume":"91","author":"DT Zhong","year":"2012","unstructured":"Zhong DT, Shi CM, Chen Q, Huang JZ, Liang JG (2012) Study on effectiveness of gemcitabine, dexamethasone, and cisplatin (GDP) for relapsed or refractory AIDS-related non-Hodgkin\u2019s lymphoma. Ann Hematol 91(11):1757\u20131763. doi: 10.1007\/s00277-012-1518-y","journal-title":"Ann Hematol"},{"issue":"2","key":"2468_CR10","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1093\/annonc\/mdl395","volume":"18","author":"F Morschhauser","year":"2007","unstructured":"Morschhauser F, Depil S, Jourdan E, Wetterwald M, Bouabdallah R, Marit G, Solal-Celigny P, Sebban C, Coiffier B, Chouaki N, Bauters F, Dumontet C (2007) Phase II study of gemcitabine-dexamethasone with or without cisplatin in relapsed or refractory mantle cell lymphoma. Ann Oncol 18(2):370\u2013375. doi: 10.1093\/annonc\/mdl395","journal-title":"Ann Oncol"},{"issue":"2","key":"2468_CR11","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1002\/cncr.21587","volume":"106","author":"J Kuruvilla","year":"2006","unstructured":"Kuruvilla J, Nagy T, Pintilie M, Tsang R, Keating A, Crump M (2006) Similar response rates and superior early progression-free survival with gemcitabine, dexamethasone, and cisplatin salvage therapy compared with carmustine, etoposide, cytarabine, and melphalan salvage therapy prior to autologous stem cell transplantation for recurrent or refractory Hodgkin lymphoma. Cancer 106(2):353\u2013360. doi: 10.1002\/cncr.21587","journal-title":"Cancer"},{"issue":"1","key":"2468_CR12","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3816\/CLM.2004.n.009","volume":"5","author":"C Emmanouilides","year":"2004","unstructured":"Emmanouilides C, Colovos C, Pinter-Brown L, Hernandez L, Schiller G, Territo M, Rosen P (2004) Pilot study of fixed-infusion rate gemcitabine with Cisplatin and dexamethasone in patients with relapsed or refractory lymphoma. Clin Lymphoma 5(1):45\u201349","journal-title":"Clin Lymphoma"},{"issue":"8","key":"2468_CR13","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1002\/cncr.20587","volume":"101","author":"M Crump","year":"2004","unstructured":"Crump M, Baetz T, Couban S, Belch A, Marcellus D, Howson-Jan K, Imrie K, Myers R, Adams G, Ding K, Paul N, Shepherd L, Iglesias J, Meyer R (2004) Gemcitabine, dexamethasone, and cisplatin in patients with recurrent or refractory aggressive histology B-cell non-Hodgkin lymphoma: a phase II study by the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG). Cancer 101(8):1835\u20131842. doi: 10.1002\/cncr.20587","journal-title":"Cancer"},{"issue":"5","key":"2468_CR14","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","volume":"25","author":"BD Cheson","year":"2007","unstructured":"Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, Coiffier B, Fisher RI, Hagenbeek A, Zucca E, Rosen ST, Stroobants S, Lister TA, Hoppe RT, Dreyling M, Tobinai K, Vose JM, Connors JM, Federico M, Diehl V, International Harmonization Project on L (2007) Revised response criteria for malignant lymphoma. J Clin Oncol 25(5):579\u2013586. doi: 10.1200\/JCO.2006.09.2403","journal-title":"J Clin Oncol"},{"issue":"8","key":"2468_CR15","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1038\/sj.bjc.6602514","volume":"92","author":"M Ng","year":"2005","unstructured":"Ng M, Waters J, Cunningham D, Chau I, Horwich A, Hill M, Norman AR, Wotherspoon A, Catovsky D (2005) Gemcitabine, cisplatin and methylprednisolone (GEM-P) is an effective salvage regimen in patients with relapsed and refractory lymphoma. Br J Cancer 92(8):1352\u20131357. doi: 10.1038\/sj.bjc.6602514","journal-title":"Br J Cancer"},{"issue":"3","key":"2468_CR16","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1159\/000077995","volume":"66","author":"A Aviles","year":"2004","unstructured":"Aviles A, Neri N, Huerta-Guzman J, Fernandez R (2004) Gemcitabine and cisplatin in refractory malignant lymphoma. Oncology 66(3):197\u2013200. doi: 10.1159\/000077995","journal-title":"Oncology"},{"issue":"4","key":"2468_CR17","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1093\/annonc\/mdp508","volume":"21","author":"PL Zinzani","year":"2010","unstructured":"Zinzani PL, Venturini F, Stefoni V, Fina M, Pellegrini C, Derenzini E, Gandolfi L, Broccoli A, Argnani L, Quirini F, Pileri S, Baccarani M (2010) Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome. Ann Oncol 21(4):860\u2013863. doi: 10.1093\/annonc\/mdp508","journal-title":"Ann Oncol"},{"key":"2468_CR18","first-page":"2728a","volume":"120","author":"A Evens","year":"2012","unstructured":"Evens A, Feldman T, Kroll A, Winer E, Flowers C, Lansigan F, Nabhan C, Nastoupil L, Kim A, Li X, Waksmundzki K (2012) Survival of newly diagnosed T-cell lymphoma (TCL) in the modern era: investigation of prognostic factors with critical examination of therapy in a multicenter US cohort. Blood (ASH Annual Meeting Abstracts) 120:2728a","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"31","key":"2468_CR19","doi-asserted-by":"crossref","first-page":"3490","DOI":"10.1200\/JCO.2013.53.9593","volume":"32","author":"M Crump","year":"2014","unstructured":"Crump M, Kuruvilla J, Couban S, MacDonald DA, Kukreti V, Kouroukis CT, Rubinger M, Buckstein R, Imrie KR, Federico M, Di Renzo N, Howson-Jan K, Baetz T, Kaizer L, Voralia M, Olney HJ, Turner AR, Sussman J, Hay AE, Djurfeldt MS, Meyer RM, Chen BE, Shepherd LE (2014) Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12. J Clin Oncol 32(31):3490\u20133496. doi: 10.1200\/JCO.2013.53.9593","journal-title":"J Clin Oncol"},{"issue":"5","key":"2468_CR20","doi-asserted-by":"crossref","first-page":"3535","DOI":"10.1007\/s12032-012-0309-6","volume":"29","author":"KL Yim","year":"2012","unstructured":"Yim KL, Ashley S (2012) Assessment of gemcitabine, cisplatin and methylprednisolone (GEM-P) combination treatment for non-Hodgkin T cell lymphoma. Med Oncol 29(5):3535\u20133539. doi: 10.1007\/s12032-012-0309-6","journal-title":"Med Oncol"},{"issue":"2","key":"2468_CR21","doi-asserted-by":"crossref","first-page":"271","DOI":"10.3324\/haematol.10737","volume":"92","author":"HT Arkenau","year":"2007","unstructured":"Arkenau HT, Chong G, Cunningham D, Watkins D, Sirohi B, Chau I, Wotherspoon A, Norman A, Horwich A, Matutes E (2007) Gemcitabine, cisplatin and methylprednisolone for the treatment of patients with peripheral T-cell lymphoma: the Royal Marsden Hospital experience. Haematologica 92(2):271\u2013272","journal-title":"Haematologica"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-015-2468-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-015-2468-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-015-2468-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T05:50:01Z","timestamp":1559022601000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-015-2468-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8,8]]},"references-count":21,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["2468"],"URL":"https:\/\/doi.org\/10.1007\/s00277-015-2468-y","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,8,8]]}}}